Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial | Synapse
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial
Key Points
Overall survival was significantly better with chemoradiotherapy compared to radiotherapy alone, enhancing treatment outcomes.
Progression-free survival rates were higher in patients receiving chemoradiotherapy with temozolomide over those treated with radiotherapy alone.
The retrospective analysis evaluated patients diagnosed with IDH wild-type gliomas, highlighting the role of molecular markers in treatment efficacy.
Findings suggest that chemoradiotherapy could be a preferred treatment option for patients with specific glioma mutations.
Abstract
The long‐term results confirmed that the OS and PFS benefits from the RT‐TMZ exceeded those of the RT alone in patients with IDH‐wt/pTERTmut gliomas with tolerable toxicity.